The Pharmacotherapy of Chronic Pain

Rheumatic Disease Clinics of North America

Volumn 34, Issue 2, 2008, Pages 369-385

  Lynch, Mary E ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; BUPRENORPHINE; CANNABINOID DERIVATIVE; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; FENTANYL; GABAPENTIN; HYDROMORPHONE; IBUPROFEN; IMIPRAMINE; MORPHINE; MUSCLE RELAXANT AGENT; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORPETHIDINE; NORTRIPTYLINE; OPIATE DERIVATIVE; OXYCODONE; PARACETAMOL; PENTAZOCINE; PETHIDINE; PREGABALIN; PROSTAGLANDIN SYNTHASE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ABDOMINAL PAIN; ALLODYNIA; ANALGESIA; ANALGESIC ACTIVITY; ANTICHOLINERGIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ANXIETY; ASTHENIA; ATAXIA; BLEEDING; BLOATING; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; DEPRESSION; DIABETIC NEUROPATHY; DIARRHEA; DISEASE CONTROL; DIZZINESS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; EUPHORIA; FACE PAIN; FIBROMYALGIA; FLUSHING; HEADACHE; HEALTH CARE ACCESS; HEALTH PROGRAM; HEARING DISORDER; HEART INFARCTION; HEART PALPITATION; HUMAN; HYPERTENSION; LIVER NECROSIS; LIVER TOXICITY; LOW BACK PAIN; LUNG INFECTION; MIGRAINE; MONOTHERAPY; NEUROPATHIC PAIN; ORTHOSTATIC HYPOTENSION; OSTEOARTHRITIS; PANIC; PARANOIA; POLYNEUROPATHY; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PSYCHOSIS; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT CANCER; REVIEW; RHEUMATOID ARTHRITIS; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; STOMACH ULCER; STROKE; TACHYCARDIA; TENSION HEADACHE; UPPER RESPIRATORY TRACT; VASODILATATION; VISUAL DISORDER; XEROSTOMIA;

ANALGESICS; DRUG THERAPY, COMBINATION; HUMANS; PAIN; RHEUMATIC DISEASES;

EID: 47049085482     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2008.04.001     Document Type: Review

References (83)

1. Carr D.B., Loeser J.D., and Morris D.B. Why narrative?. In: Carr D.B., Loeser J.D., and Morris D.B. (Eds). Narrative, pain, and suffering (2005), IASP Press, Seattle (WA) 1-13
2. Lynch M.E., and Watson C.P. The pharmacotherapy of chronic pain, a review. Pain Res Manag 11 (2006) 11-38
3. Gilron I., Bailey J.M., Dongsheng T., et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352 (2005) 1324-1334
4. Tannenbaum H., Bombardier C., Davis P., et al. An evidence based approach to prescribing NSAIDs. The Third Canadian Consensus Conference. J Rheumatol 33 (2006) 140-157
5. Hogestatt E.D., Jonsson B.A.G., Ermund A., et al. Conversion of acetaminophen to bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 280 (2005) 31405-31412
6. Lynch M.E. Antidepressants as analgesics. A review of random controlled trials examining analgesic effects of antidepressant agents. J Psychiatry Neurosci 26 (2001) 30-36
7. McQuay H.J., and Moore R.A. Antidepressants and chronic pain. BMJ 314 (1997) 763-764
8. McQuay H.J., Tramer M., Nye B.A., et al. A systematic review of antidepressants in neuropathic pain. Pain 68 (1996) 217-227
9. Tasmuth T., Hartel B., and Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain 6 (2002) 17-24
10. Sindrup S.H., Bach F.W., Madsen C., et al. Venalfaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 60 (2003) 1284-1289
11. Rowbotham M., Goli V., Kunz N.R., et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110 (2004) 697-706
12. Forssell H., Tasmuth T., Tenovuo O., et al. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J Orofac Pain 18 (2004) 131-137
13. Yucel A., Ozyalcin S., Koknel Talu G., et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: a double blind, placebo controlled study. Eur J Pain 9 (2005) 406-416
14. Ozyalcin S.N., Koknel Talu G., Kiziltan E., et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 45 (2005) 144-152
15. Reuben S.S., Makari-Judson G., and Lurie S.D. Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. J Pain Symptom Manage 27 (2004) 133-139
16. Goldstein D.J., Lu Y., Detke M.J., et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116 (2005) 109-118
17. Wernicke J.F. Duloxetine in treatment of diabetic neuropathic pain. Pharmacotherapy 24 (2004) 1422 abstract 17
18. Raskin J., Pritchett Y.L., Wang F., et al. A double blind, randomized multicenter trial comparing duloxetine with placebo in management of diabetic peripheral pain. Pain Med 5 (2005) 346-356
19. Wernicke J.F., Pritchett Y.L., D'Souza D.N., et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67 (2006) 1411-1420
20. Arnold L.M., Lu Y., Crofford I.J., et al. A double-blind, multicenter trial comparing duloxetine with placebo in treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50 (2004) 2974-2984
21. Arnold L.M., Rosen A., Pritchett Y.L., et al. A randomized double blind, placebo-controlled trial of duloxetine in the treatment of women with fibyalgia with and without major depressive disorder. Pain 119 (2005) 5-15
22. Brannan S.K., Mallinckrodt C.H., Brown E.B., et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 39 (2005) 43-53
23. Fava M., Mallinckrodt C.H., Detke M.J., et al. The effect of duloxetine on painful physical symptoms in depressed patients: Do improvements in these symptoms result in higher remission rates?. J Clin Psychiatry 65 (2004) 521-530
24. Goldstein D.J., Detke M.J., and Iyengar S. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 45 (2004) 17-28
25. Arnold L.M., Goldenberg D.L., Stanford S.B., et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 56 (2007) 1336-1344
26. Crofford L.J., Rowbotham M.C., Mease P.J., et al. Pregabalin for treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 1264-1273
27. Griffin R.S., and Woolf C.J. Pharmacology of analgesia. Principles of pharmacology: the pathophysiologic basis of drug therapy (2005), Lippincott, Williams and Wilkins, Philadelphia 229-243
28. Rogawski M.A., and Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 10 (2004) 685-692
29. Rice A.S.C., Maton S., and PNS Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 94 (2001) 215-224
30. Rowbotham M., Harden N., Stacey B., et al. Gabapentin for the treatment of postherpetic neuralgia. JAMA 280 (1998) 1837-1842
31. Morello C.M., Leckband S.G., Stoner C.P., et al. Randomized double blind study comparing efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 159 (1999) 1931-1937
32. Backonja M., Baydoun A., Edwards K.R., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 280 (1998) 1831-1836
33. Gorson K.C., Schott C., Herman R.M., et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled trial. J Neurol Neurosurg Psychiatry 66 (1999) 251-252
34. Serpell M.G., and NPS Group. Gabapentin in neuropathic pain syndromes: a randomised, double blind, placebo-controlled trial. Pain 99 (2002) 557-566
35. Levendoglu F., Ogun C.O., Ozerbil O., et al. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine 29 (2004) 743-751
36. Pandey C.K., Bose N., Garg G., et al. Gabapentin for the treatment of pain in Guillain-Barre syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg 95 (2002) 1719-1723
37. Bone M., Critchley P., and Buggy D.J. Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med 27 (2002) 481-486
38. Spira P.J., Beran R.G., and AGCDH Group. Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo-controlled study. Neurology 61 (2003) 1753-1759
39. Dworkin R.H., Corbin A.E., Young J.P., et al. Pregabalin for treatment of postherpetic neuralgia, a randomized, placebo-controlled trial. Neurology 60 (2003) 1274-1283
40. Sabatowski R., Galvez R., Cherry D.A., et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomized, placebo-controlled clinical trial. Pain 109 (2004) 26-35
41. Freynhagen R., Strojek K., Griesing T., et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicenter, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115 (2005) 254-263
42. van Seventer R., Feister H.A., Young J.P.J., et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13 week, randomized trial. Curr Med Res Opin 22 (2006) 375-384
43. Richter R.W., Portenoy R.K., Sharma U., et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo controlled trial. J Pain 6 (2005) 253-260
44. Lesser H., Sharma U., LaMoreaux L., et al. Pregabalin relieves symptoms of painful diabetic neuropathy. Neurology 63 (2004) 2104-2110
45. Rosenstock J., Tuchman M., LaMoreaux L., et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 110 (2004) 628-638
46. Siddall P.J., Cousins M.J., Otte A., et al. Pregabalin in central neuropathic pain associated with spinal cord injury, a placebo-controlled trial. Neurology 67 (2006) 1792-1800
47. Schumacher H.E., Basbaum A.I., and Way W.L. Opioid analgesics and antagonists. In: Katzung B.G. (Ed). Basic and clinical pharmacology. 9th edition (2004), Lange Medical Books, McGraw-Hill, New York 497-518
48. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 332 (1995) 1685-1690
49. Furlan A.D., Sandoval J.A., Mailis-Gagnon A., et al. Opioids for chronic noncancer pain: meta-analysis of effectiveness and side effects. CMAJ 174 (2006) 1589-1594
50. Jovey R.D., Ennis J., Gardner-Nix J., et al. Use of opioid analgesics for the treatment of chronic noncancer pain-a consensus statement and guidelines from the Canadian Pain Society, 2002. Pain Res Manag 8 (2003) 3A-28A
51. Lynch M.E. A review of the use of methadone for treatment of chronic non-cancer pain. Pain Res Manage 10 (2005) 133-144
52. Rice A.S.C. Cannabinoids and pain. Curr Opin Investig Drugs 2 (2001) 399-413
53. Lynch M.E. Preclinical science regarding cannabinoids as analgesics: an overview. Pain Res Manage 10 (2005) 7A-14A
54. Pertwee R.G. Cannabinoid receptors and pain. Prog Neurobiol 63 (2001) 569-609
55. Walker J.M., Strangman N.M., and Huang S.M. Cannabinoids and pain. Pain Res Manage 6 (2001) 74-79
56. Rice A.S.C. Cannabinoids. In: McMahon S., and Koltzenburg M. (Eds). Wall and Melzack's textbook of pain. Online edition (2008), Philadelphia: Elsevier 521-540
57. Lynch ME. Pharmacotherapy of chronic pain. In: Taenzer P, Rashiq S, Schopflocher D, editors. Health policy perspectives on chronic pain. Institute of Health Economics: Edmonton (Canada), in press.
58. Abrams D., Jay C.A., Shade S.B., et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized controlled trial. Neurology 68 (2007) 515-521
59. Rog D.J., Nurmikko T.J., Friede T., et al. Randomized controlled trial of cannabis based medicine in central pain due to multiple sclerosis. Neurology 65 (2005) 812-819
60. Notcutt W., Price M., Miller R.D., et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anesthesia 59 (2004) 440-452
61. Wade D.T., Robson P., House H., et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 17 (2003) 21-29
62. Wade D.T., Makela P., Robson P., et al. Do cannabis based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10 (2004) 434-441
63. Berman J.S., Symonds C., and Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Pain 112 (2004) 299-306
64. Zajicek J., Fox P., Sanders H., et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362 9395 (2003) 1517-1526
65. Zajicek J.P., Sanders H.P., Wright D.E., et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow-up. J Neurol Neurosurg Psychiatry 76 (2005) 1664-1669
66. Wissell J., Haydn T., Muller J.E., et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain. J Neurol 253 (2006) 1337-1341
67. Pinsger M., Schimetta W., volc D., et al. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain-a randomized controlled trial. Wein Klin Wochenschr 118 (2006) 327-335
68. Svendsen K.B., Jensen T.S., and Bach F.W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 329 7460 (2004) 253
69. Karst M., Salim K., Burstein S., et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. JAMA 290 (2003) 1757-1762
70. Maurer M., Henn V., Dittrich A., et al. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci 240 (1990) 1-4
71. Holdcroft A., Smith M., Jacklin A., et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anesthesia 52 (1997) 483-488
72. Noyes R.J., Smith M., Jacklin A., et al. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol 1 (1975) 139-143
73. Noyes R.J., Brunk S.F., Avery D.H., et al. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 18 (1975) 84-89
74. Staquet M., Gantt C., and Machin D. Effect of a nitrogen analog of tetrahydrocannabinol on cancer pain. Clin Pharmacol Ther 23 (1978) 397-401
75. Jochimsen P.R., Lawton R.L., VerSteeg K., et al. Effect of benzopyranopyridine a delta-9-THC cogener on pain. Clin Pharmacol Ther 24 (1978) 223-227
76. Clark A.J., Lawton R.L., VerSteeg K., et al. Guidelines for the use of cannabinoid compounds in chronic pain. Pain Res Manage 10 (2005) 44A-46A
77. Clark AJ, Lynch ME, Ware M, et al. Updated guidelines for the use of cannabinoid compounds available in Canada for the treatment of chronic pain [abstract]. ICRS Annual Meeting Abstracts; 2007. p. 126.
78. Watson S.J., Benson Jr. A.J., and Joy J.E. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine Report. Arch Gen Psychiatry 57 6 (2000) 547-552
79. Clark A.J., Ware M.A., Yazer E., et al. Patterns of cannabis use among patients with multiple sclerosis. Neurology 62 (2004) 2098-2100
80. Ware M.A., Doyle C.R., Woods R., et al. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain 102 1-2 (2003) 211-216
81. Ogborne A.C., Smart R.G., and Adlaf E.M. Self-reported medical use of marijuana: a survey of the general population. CMAJ 162 (2000) 1685-1686
82. Van Tulder M.W., Touray T., Furlan A.D., et al. Muscle relaxants for nonspecific low back pain. Cochrane Database Syst Rev 4 (2003) CD004252, 10.1002/14651858
83. Hashibe M., Morgenstern H., Cui Y., et al. Marihuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev 15 (2006) 1829-1834